How MannKind’s (MNKD) Rising Revenue but Renewed Losses Could Reshape Its Growth Investment Story
MannKind Corporation recently reported rising second-quarter 2026 revenue to US$109.37 million, but also a shift from profit to a net loss of US$19.03 million. This return to losses, despite higher revenue, highlights pressure from the company's cost base. The article suggests that while the Technosphere platform and programs like Afrezza and INFLO 1 data for nintedanib DPI offer potential, increasing R&D and commercial costs remain a significant risk to future profitability.
Research Analysts Set Expectations for MannKind Q3 Earnings
HC Wainwright has lowered its Q3 2026 EPS estimate for MannKind to a loss of $0.10, and also reduced full-year estimates through 2030, citing weaker near-term profitability. Despite these revisions, analyst sentiment for MannKind remains largely positive with a consensus "Moderate Buy" rating and a $9.22 target price. The biopharmaceutical company's shares opened down 3.1%, and a director recently sold a significant number of shares.
Rubric Capital discloses 5.83% MannKind Corporation (MNKD) stake
Rubric Capital Management LP and David Rosen have reported a passive ownership stake of 5.83% in MannKind Corporation (MNKD), holding 18,000,000 shares with shared voting and dispositive power. This percentage is based on 308,950,166 shares outstanding as of April 24, 2026. Rubric Capital Master Fund LP is noted as having the right to receive dividends and sale proceeds from over 5% of the common stock.
MannKind FY2029 EPS Estimate Decreased by HC Wainwright
HC Wainwright has reduced its FY2029 EPS estimate for MannKind (NASDAQ:MNKD) to $0.27 from $0.39, while maintaining a "Buy" rating. Despite this revision, the biopharmaceutical company holds a "Moderate Buy" consensus rating from analysts, with an average price target of $9.22. MannKind shares opened at $3.85, and institutional investors own nearly half of the stock.
Is MannKind (MNKD) Undervalued After Positive INFLO 1 Data For Its IPF Pipeline?
MannKind (MNKD) has seen increased investor interest following positive Phase 1b INFLO-1 data for its inhaled nintedanib therapy, leading to a recent stock price jump. Despite short-term momentum, the stock remains down year-to-date and over a three-year period. A widely followed narrative suggests MannKind is undervalued with a fair value of $7.59, driven by Afrezza's growth and pipeline potential, although execution risks exist.
Mannkind director Steven Binder sells $158,547 in common stock
Steven B. Binder, a director at MannKind Corp, sold 39,051 shares of common stock for $158,547 on August 7, 2026, at an average price of $4.06 per share. This sale was conducted via a Rule 10B5-1 trading plan established in December 2025. Despite recent losses, analysts forecast positive earnings and strong revenue growth for MannKind, supported by its expanding product portfolio and recent FDA approvals.
Mannkind director Steven Binder sells $158,547 in common stock By Investing.com
Mannkind director Steven B. Binder sold 39,051 shares of the company's common stock for a total of $158,547 on August 7, 2026, as part of a Rule 10B5-1 trading plan. Despite a recent loss per share, analysts predict positive earnings for fiscal 2026 with strong revenue growth. Recent reports show MannKind Corp. surpassed revenue expectations and received a reiterated Buy rating from H.C. Wainwright due to FDA approvals and promising clinical data.
Mannkind director Steven Binder sells $158,547 in common stock By Investing.com
Steven B. Binder, a director at MannKind Corp (NASDAQ:MNKD), sold 39,051 shares of common stock for $158,547 on August 7, 2026, as part of a Rule 10B5-1 trading plan. Following the sale, Binder directly holds 785,867 shares. Despite a recent loss per share, analysts predict positive earnings for fiscal 2026, supported by strong revenue growth and recent FDA approvals for the company's products.
MannKind Corp (MNKD) Director Steven Binder Sells 39,051 Shares
MannKind Corp Director Steven Binder sold 39,051 shares of MNKD on August 7, 2026, for approximately $158,547, increasing his total sales over the past year to 108,476 shares. This insider selling trend, with 12 sells against 1 buy, contrasts with institutional activity where 4 out of 5 gurus increased their holdings. GuruFocus rates MNKD as a "Possible Value Trap, Think Twice" given its price-to-GF-Value ratio of 0.55, suggesting caution despite its apparent undervaluation.
Sei Investments Co. Buys 253,537 Shares of MannKind Corporation $MNKD
Sei Investments Co. significantly increased its stake in MannKind Corporation (NASDAQ:MNKD) by 53.6% in the first quarter, purchasing an additional 253,537 shares, bringing its total holdings to 726,396 shares valued at approximately $1.78 million. Institutional investors collectively own 49.55% of MannKind, a biopharmaceutical company focused on inhaled therapeutic products. Despite recent positive institutional activity, the stock trades at a negative price-to-earnings ratio, and while analysts maintain a "Moderate Buy" consensus, several have recently reduced their price targets.
First Trust Advisors LP Raises Stake in MannKind Corporation $MNKD
First Trust Advisors LP significantly increased its stake in MannKind Corporation (NASDAQ:MNKD) by 48% in the first quarter, now owning 869,254 shares valued at $2.13 million. Despite institutional investors holding 49.55% of the company, MannKind recently missed earnings expectations with a loss of $0.05 per share and revenue of $90.17 million. Analysts hold a "Moderate Buy" consensus with an average price target of $9.22, significantly above the current stock price of $4.11, although some ratings were mixed.
MannKind (NASDAQ:MNKD) Rating Lowered to Sell at Wall Street Zen
Wall Street Zen downgraded MannKind (NASDAQ:MNKD) from "hold" to "sell," despite a broader analyst consensus of "Moderate Buy" with an average price target of $9.22. The biopharmaceutical company's shares opened at $4.11, up 5.7%, but reported a Q1 loss of $0.05 per share and revenue of $90.17 million, both missing analyst expectations. Institutional investors own nearly half of MannKind's stock, with Vanguard and State Street increasing their positions, while a director recently sold shares to cover tax obligations.
MannKind (MNKD) insider Steven Binder plans 39,051-share Rule 144 stock sale
MannKind Corporation insider Steven Binder plans to sell up to 39,051 common shares under Rule 144 through Morgan Stanley Smith Barney LLC. This filing also discloses previous 10b5-1 plan sales by Binder, including 52,485 shares on July 17, 2026, and 16,940 shares on May 12, 2026. The planned sale involves shares associated with Performance Stock Units.
MannKind Corp Q2 2026: Revenue $109.4M, EPS $(0.06) — 10-Q Summary
MannKind Corp reported its second-quarter 2026 results, showing a significant increase in revenue to $109.4M, up from $76.5M in the prior year, primarily due to the acquisition of scPharma and the addition of Furoscix. Despite revenue growth, the company recorded a net loss of $(19.0)M and diluted EPS of $(0.06) for the quarter. Key business developments included FDA approval for Afrezza's expanded label and Furoscix ReadyFlow autoinjector, alongside progress in their pipeline with MNKD-201 and MNKD-701.
MannKind's Diversified Portfolio Seen Leading to Higher Revenue in H2, Wedbush Says
Wedbush analysts anticipate higher revenue for MannKind in the second half of the year due to its increasingly diversified portfolio. The company's focus for 2026 is on commercial and clinical execution, with Furoscix therapy being a key priority.
MannKind Reports Second Quarter 2026 Financial Results and Provides Business Update
MannKind Corporation reported strong Q2 2026 financial results with total revenues of $109.4 million, a 43% increase year-over-year. The company highlighted three major catalysts for future growth: the launch of Afrezza's pediatric indication, FDA approval of the Furoscix ReadyFlow™ autoinjector, and positive Phase 1b data for nintedanib DPI. These achievements are expected to fuel near-term growth and validate MannKind's diversification strategy.
MannKind earnings in focus after FUROSCIX ReadyFlow approval
MannKind Corp is set to release its second-quarter earnings, with analysts anticipating a loss of 1 cent per share on revenue of $109.02 million, reflecting a significant year-over-year increase. The biopharmaceutical company is expected to capitalize on the recent FDA approval of FUROSCIX ReadyFlow, which analysts believe could be transformative for its revenue growth. Investors will be keenly watching for management commentary on the launch trajectory of ReadyFlow and updates on its dry powder inhaler pipeline.
MannKind Q2 2026 Earnings: Revenue Rises 43% as Costs Drive a Net Loss
MannKind Corporation reported a 43% increase in Q2 2026 revenue, reaching $109.4 million, primarily due to the acquisition of scPharma and increased collaboration income. However, the company experienced a net loss of $19.0 million, an adverse swing from a profit of $0.7 million in Q2 2025, driven by higher launch spending for Furoscix and pediatric Afrezza, increased R&D, and significant financing costs. Key approvals for pediatric Afrezza and Furoscix ReadyFlow are expected to expand commercial opportunities, but investors are monitoring launch execution, margin pressures, and pipeline progress.
MNKD Stock Jumps On Receiving FDA Approval For Afrezza To Treat Diabetes In Children
MannKind Corporation's (MNKD) stock gained about 5% after the FDA approved its Afrezza Inhalation Powder for children and adolescents aged 6 and older with type 1 and type 2 diabetes. This makes Afrezza the first and only needle-free, inhaled mealtime insulin available for pediatric patients, who previously relied on injections or pumps. The approval was supported by positive data from the Phase 3 INHALE-1 study, demonstrating Afrezza's efficacy and patient satisfaction compared to traditional methods.
MannKind Corp (MNKD) Financial Health: Profitability & Balance Sheet Analysis
MannKind Corp (MNKD) has a current financial score of 7.90, ranking 72 out of 384 in its industry, indicating weak financial status but high operating efficiency. The company recently reported a quarterly revenue of $90.17 million, marking a 15.08% year-over-year increase, and its net profit surged by 226.30% year-over-year. While key financial metrics like cash and equivalents, total assets, liabilities, and free cash flow are mentioned, the specific data values for these categories have not yet been disclosed by the company.
Vanguard Capital Management (MNKD) discloses 15.45M-share, 5% MannKind position
Vanguard Capital Management LLC and its affiliates have reported a passive 5% ownership stake in MannKind Corp (MNKD), holding 15,450,421 shares as of June 30, 2026. This disclosure was made via a Schedule 13G filing, indicating Vanguard's sole voting power over 2,281,029 shares and sole dispositive power over all its MannKind holdings. The investment is spread across various Vanguard funds and managed accounts, with no single underlying investor holding more than 5% through these positions.
MannKind stock reiterated at Buy by H.C. Wainwright on trial data
H.C. Wainwright has reiterated a Buy rating and a $10.00 price target for MannKind (NASDAQ:MNKD) after positive INFLO-1 trial data for its nintedanib dry powder inhaler. The trial showed good tolerability with no severe adverse events. This news comes alongside recent FDA approvals for MannKind's FUROSCIX ReadyFlow and Afrezza Inhalation Powder, which are expected to contribute to the company's profitability this year.
MannKind stock reiterated at Buy by H.C. Wainwright on trial data
H.C. Wainwright reiterated a Buy rating and a $10.00 price target for MannKind (NASDAQ:MNKD) after positive results from the INFLO-1 trial for its nintedanib dry powder inhaler. The trial showed good tolerability with no severe adverse effects, supporting the drug's development for idiopathic pulmonary fibrosis. The firm also highlighted recent FDA approvals for FUROSCIX ReadyFlow and expanded use of Afrezza, alongside an upcoming PDUFA date, as significant catalysts for MannKind's growth.
MNKD|MannKind Corp|Price:4.115|Chg%:+0.265
This analysis of MannKind Corp (MNKD) by TradingKey highlights its strong fundamentals, high growth potential, and fair valuation within the Biotechnology & Medical Research industry. Despite recent weak stock market performance, the company shows significant institutional ownership and positive analyst ratings with a high price target. The stock is currently trading sideways, suggesting suitability for range-bound swing trading.
MNKD: Phase I-B data show nintedanib DPI is safe and well-tolerated in IPF, enabling phase II advancement
MannKind Corporation (MNKD) announced positive Phase I-B results for its nintedanib Dry Powder Inhaler (DPI) in Idiopathic Pulmonary Fibrosis (IPF) patients. The study demonstrated strong safety and tolerability, with no serious adverse events and effective lung delivery, paving the way for a global Phase II trial. This advancement supports the evaluation of nintedanib DPI as both monotherapy and in combination treatments for IPF.
MannKind’s Inhaled Nintedanib Passes Safety Test in IPF Patients, Paving Way for Global Phase 2 Trial
MannKind's inhaled nintedanib therapy for Idiopathic Pulmonary Fibrosis (IPF) successfully cleared a Phase 1b safety study, demonstrating no serious adverse events or significant gastrointestinal side effects in 27 patients. This positive outcome, building on earlier healthy volunteer data, paves the way for a global Phase 2 trial. The company aims to provide an alternative to oral nintedanib, which is often limited by systemic side effects, by delivering the drug directly to the lungs, potentially reducing adverse reactions like cough.
MNKD|MannKind Corp|Price:3.855|Chg%:-0.055
This article provides a detailed financial overview of MannKind Corp (MNKD), including its latest earnings report, revenue, EPS, and analyst ratings. It presents comprehensive quarterly and annual financial statements, such as the income statement, balance sheet, and cash flow statement, with year-on-year changes for various financial indicators. The content also addresses frequently asked questions regarding the company's financial performance in FY2025.
MannKind to Report Second Quarter Financial Results and Host Conference Call on August 5, 2026
MannKind Corporation (MNKD) will release its second quarter financial results on August 5, 2026, after the market closes. The company will also host a conference call and webcast at 5:00 PM ET on the same day to discuss the results and provide a business update. Participants can access the webcast or dial into the conference call using the provided details.
MNKD: Nintedanib DPI demonstrated strong safety and tolerability in IPF, supporting Phase 2 advancement
MannKind Corporation (MNKD) has announced Phase 1b results for nintedanib DPI, showing it to be safe and well-tolerated in Idiopathic Pulmonary Fibrosis (IPF) patients. The study reported no serious adverse events or discontinuations, with only mild, transient coughs. These positive results support the advancement of nintedanib DPI into an ongoing Phase 2 trial, which will further evaluate its safety, tolerability, and efficacy.
MannKind Corp (MNKD) Technical Analysis: Support, Resistance, Indicators & Moving Averages
This article provides a technical analysis of MannKind Corp (MNKD), detailing its price momentum score within the Biotechnology & Medical Research industry. It outlines the stock's current trading range between support and resistance levels, and analyzes various technical indicators like MACD, RSI, and Moving Averages to offer a "Neutral" overall signal. The report also includes FAQs explaining technical ratings and moving averages for investor reference.
MannKind to Report Second Quarter Financial Results and Host Conference Call on August 5, 2026
MannKind Corporation (MNKD) announced it will release its second-quarter 2026 financial results on August 5, 2026, after market close. The company will also host a conference call and webcast on the same day at 4:30 p.m. ET to discuss these results and provide a business update.
MannKind will review second-quarter results in Aug. 5 webcast
MannKind Corporation (Nasdaq: MNKD) announced it will report its second-quarter 2026 financial results after market close on Wednesday, August 5, 2026. The management team will host a conference call and live webcast at 4:30 p.m. Eastern Time to review the results and provide a business update, with a replay available on their investor relations website for approximately 90 days. This announcement follows recent positive news including a $50 million private placement and FDA approval for Furoscix ReadyFlow™.
H.C. Wainwright reiterates MannKind stock rating on FDA approval
H.C. Wainwright maintained a Buy rating and a $10.00 price target for MannKind (NASDAQ:MNKD) after the FDA approved FUROSCIX ReadyFlow, citing a potential upside of 142%. The firm expects ReadyFlow, an autoinjector for furosemide, to significantly boost revenue and margins starting in 2027, especially through hospital discharge pathways. MannKind also received FDA approval for Afrezza inhaled insulin for children and completed randomization for its Phase 1b INFLO-1 clinical trial, with results expected in Q3 2026.
MannKind Corp (MNKD) Cash Flow
This article provides a comprehensive overview of MannKind Corp's (MNKD) cash flow, including operating, investing, and financing activities across various fiscal quarters. It details changes in key cash flow metrics such as net income, capital expenditures, and free cash flow over time, presenting raw figures and percentage changes. Additionally, it offers explanations of these cash flow components and their significance for investors.
FDA Approves Mannkind's At-Home Treatment Option for Heart Failure or Kidney Disease
Mannkind Corporation announced that the FDA has approved Furoscix ReadyFlow, an at-home furosemide injection for adults with heart failure or chronic kidney disease. This approval makes Furoscix ReadyFlow the first autoinjector to deliver IV-equivalent exposure for treating edema. The company also secured $50 million in private placement financing, partly to fund a $45 million contingent value rights payment triggered by this FDA approval.
MNKD|MannKind Corp|Price:4.130|Chg%:+0.240
MannKind Corporation (MNKD) is a biopharmaceutical company specializing in treatments for cardiometabolic and orphan lung diseases, including diabetes and pulmonary hypertension. Key commercial products include Afrezza, FUROSCIX, V-Go, and Tyvaso DPI. The article provides company details, executive shareholdings, and institutional ownership data, noting increased institutional holdings in Q1 2026 and product sales as the biggest revenue source.
MannKind Corp (MNKD) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article provides a detailed breakdown of MannKind Corp's (MNKD) revenue for fiscal year 2025, categorized by business segments and geographic region. Product sales constitute the largest portion at 62.05%, followed by royalties and services. The company's entire reported revenue for this period originates from the United States.
MannKind Corp (MNKD) Dividends & Stock Splits: Historical Payouts and Event Timeline
This article provides an overview of MannKind Corp (MNKD) focusing on its dividend history and stock splits. It indicates that the company has distributed $0.00 in dividends over the past five years and contains no specific dividend or stock split data. The page also presents current stock performance details like market cap and P/E ratio.
MannKind Corporation Revenue Breakdown – DUS:NNFN
This article details MannKind Corporation's revenue breakdown, highlighting that the company generated 297.12 million EUR last year, primarily from its Innovative Therapeutic Products and Devices segment. The United States was the largest geographical contributor to this revenue.
The Bull Case For MannKind (MNKD) Could Change Following FDA Approval Of At-Home Furoscix ReadyFlow Autoinjector – Learn Why
MannKind Corporation recently received FDA approval for Furoscix ReadyFlow, an at-home autoinjector for treating edema in heart failure and chronic kidney disease patients. This approval introduces a new at-home care option and could influence MannKind's investment narrative, although the company still faces challenges with managing losses and expanding beyond its current core products. Despite this positive development, the company's financial outlook and reliance on external funding remain key factors for investors to consider.
MannKind Corporation (MNKD) stock price, news, quote and history
This article provides a comprehensive overview of MannKind Corporation (MNKD) stock, including its current price, historical performance, key financial metrics, and analyst insights. It details the company's biopharmaceutical focus on chronic disease care, its product offerings like Afrezza and Tyvaso DPI, and its pipeline. The company's stock shows a current price of 4.13 with a market cap of 1.276B and outlines performance against the S&P 500.
FDA Approves Mannkind's At-Home Treatment Option for Heart Failure or Kidney Disease
The FDA has approved MannKind's Furoscix ReadyFlow, an autoinjector delivering furosemide for edema in adults with heart failure or chronic kidney disease, allowing for at-home treatment. This approval triggered a $45 million contingent value rights payment, which MannKind plans to fund through a $50 million private placement. MannKind's stock has shown recent gains but momentum indicators suggest potential fading.
MannKind shares surge after FDA approves Furoscix ReadyFlow and company secures $50 million financing
MannKind Corporation's shares rose by approximately 6% following FDA approval for its Furoscix ReadyFlow autoinjector, a new and faster treatment for oedema in heart failure and chronic kidney disease patients. The company also announced a $50 million private placement, with proceeds intended for general corporate purposes, including a $45 million contingent value rights payment related to the FDA approval. Furoscix ReadyFlow is expected to be commercially available in the U.S. before the end of August.
MannKind stock jumps 6% on FDA approval, $50M financing
MannKind Corporation (NASDAQ:MNKD) shares increased by 6% following FDA approval for Furoscix ReadyFlow, an autoinjector designed for at-home treatment of edema in adults with heart failure or chronic kidney disease. The company also announced a $50 million private placement, with proceeds intended for general corporate purposes, including a $45 million contingent value rights payment triggered by the FDA approval. Furoscix ReadyFlow is expected to be commercially available in the U.S. by the end of August.
MannKind closes $50M financing, wins FDA nod for Furoscix auto-injector
MannKind (Nasdaq:MNKD) has announced it secured $50 million in a private placement and received FDA approval for its Furoscix ReadyFlow auto-injector. Frazier Life Sciences led the financing, which is expected to close today, July 24. The proceeds will be used for general corporate purposes, including a $45 million contingent value rights payment triggered by the FDA approval.
MannKind Announces $50 Million Private Placement
MannKind Corporation announced a private placement totaling $50 million, led by Frazier Life Sciences. The funding will be used for general corporate purposes, including a $45 million contingent value rights payment triggered by the recent FDA approval of Furoscix ReadyFlow™. The company is selling common stock and pre-funded warrants to institutional investors at $3.89 per share and $3.88 per pre-funded warrant, respectively.
MannKind Corporation (MNKD) stock price, news, quote and history
This article provides a comprehensive overview of MannKind Corporation (MNKD), detailing its current stock price, financial statistics, and company profile. It includes stock performance data, analyst insights, and comparisons with similar biotechnology and healthcare companies. The content also highlights MannKind's focus on solutions for chronic disease care and its product pipeline.
At-home autoinjector delivers IV-equivalent therapy in under 10 seconds
MannKind Corporation (Nasdaq: MNKD) has received FDA approval for Furoscix ReadyFlow, an autoinjector delivering IV-equivalent diuretic therapy for edema in adults with heart failure or chronic kidney disease. This new device provides an 80 mg/mL furosemide dose in less than 10 seconds, significantly reducing the administration time compared to the existing Furoscix On-body infusor, which takes about five hours. The product is expected to be commercially available in the U.S. by the end of August 2026, offering a convenient at-home treatment option to potentially reduce hospital visits and improve patient care.
MannKind Announces $50 Million Private Placement
MannKind Corporation announced a $50 million private placement with certain institutional investors, led by Frazier Life Sciences. The biopharmaceutical company will use the net proceeds for general corporate purposes, including a $45 million contingent value rights payment related to the recent FDA approval of Furoscix ReadyFlow™. The placement involves the sale of common stock and pre-funded warrants.
Form 4 MannKind Corp For: 21 July By Investing.com
This article is a brief financial bulletin from Investing.com, reporting a Form 4 filing for MannKind Corp on July 21. It mentions that shares of MNKD were down 5.19% and concludes with additional market data and related news.
